Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma
A case report and literature review

Jingxia Jin, MM, Cuiping Zheng, MM*, Shenghao Wu, MM

Abstract
Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a kind of rare peripheral T cell lymphoma, which usually has acute onset at old age.

Materials and methods: Here we report a case of relapsed refractory AITL, which has achieved obvious curative effect after treatment with chidamide.

Results: Initially, the patient received 7 courses of treatment with recombinant human endostatin (endostar)+CHOP. The patient achieved complete remission, but suffered from recurrence later. After changing chemotherapy regimens, the outcome was still not satisfactory, and the patient developed systemic skin infiltration and rashes. After 2 courses of chemotherapy with chidamide (30mg) twice a week + intravenous injections with cyclophosphamide (0.1g) twice every other day + thalidomide (50mg) every night, the patient began with the oral intake of chidamide, and the therapeutic effect was satisfactory, with diminishing systemic rashes and shrunken lymph nodes.

Discussion and conclusions: Chidamide has good therapeutic effect in the treatment of AITL, which provides a novel therapeutic strategy for relapsed refractory AITL. However, more cases are still needed to further validate its efficacy.

Abbreviations: AITL = angioimmunoblastic T-cell lymphoma, CR = complete remission, CT = computed tomography, DFS = disease-free survival, EBV = Epstein–Barr virus, ORR = objective response rate, OS = overall survival, PET = positron emission tomography, PFS = progression-free survival.

Keywords: chemotherapy, chidamide, relapsed refractory angioimmunoblastic T-cell lymphoma

1. Introduction
Angioimmunoblastic T-cell lymphoma (AITL) is a kind of rare peripheral T cell lymphoma, which accounts for 2% of non-Hodgkin lymphoma.1 and 15%–20% of T-cell lymphoma. AITL usually has acute onset at old age, and the incidence of AITL in males is close to females.1,2,3 The median age of onset for AITL is 65 years. It usually has aggressive progression and poor prognosis. The main manifestations of AITL include systemic lymphadenopathy, fever, hepatosplenomegaly, and rash.1,2,4-6 AITL is pathologically characterized by the abnormal clonal proliferation of T cells, accompanied by significant vascular hyperplasia and follicular dendritic cell proliferation. The immunophenotypic characteristics of AITL represent the increased number of interfollicular CD3+ T cells (mostly CD3+CD4+ cells). The immunophenotypes of large lymphoblasts among follicles are CD20 and CD79 positive. Immunophenotypes of follicular dendritic cells with typical features of AITL are CD21, CD23, or CD35 positive.4 At present, the treatment for AITL is the same with that for aggressive lymphoma. Chemotherapy for AITL usually uses CHOP, ECHOP, hyper-CAVD, or MINE. However, their therapeutic effects are not satisfactory, with the 5-year progression-free survival rate of 13%–23%, and the 5-year survival rate of 30%. After complete remission (CR), high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation can improve the overall survival (OS) rate and disease-free survival (DFS) rate. Up to now, there has been no standard treatment plan for AITL, and large-scale prospective studies on the treatment of AITL are also rarely seen. Chidamide, a selective oral inhibitor for histone deacetylase, is the first new drug approved for the treatment of relapsed or refractory peripheral T cell lymphoma in China. Herein, we report a case of refractory AITL admitted at our hospital, which has achieved obvious curative effect after treatment with chidamide.

2. Case report
A 60-year old married female, with more than 1 year of cough, pharyngalgia, and systemic lymphadenopathy and 1 week of rash, was admitted at our hospital on March 9th 2016. Prior written and informed consent was obtained from the patient, and the study was approved by the local ethics review board. On admission, physical
examination showed pharyngeal hyperemia, lymph node enlargement at neck, double axilla, and inguinal with press pain (1–2 cm in diameter), and rashes at trunk and limbs. Heart and lung functions were normal. Lymph node biopsy showed lymph node hyperplastic lesions, which met the diagnostic standards for AITL. Results from immunohistochemistry showed that, M15-0453: Bcl-6 (partially+), CD10 (partially+), CD20 (partially+), CD21 (majorly+), Ki-67 (30%–40%), TIA 1 (scattered minority+). M15-0453: EBER (very few+). Bone marrow examination showed bone marrow hyperplasia, and active proliferation of granulocytes and erythrocytes. Epstein–Barr virus (EBV) quantification was 9.8E+5 copies/mL. Examination of EBV-IgM antibody showed weak positive results. Abdominal computed tomography (CT) showed splenomegaly, multiple infarct foci in spleen, and multiple lymph node enlargement at abdominal cavity, retroperitoneum, and bilateral inguens. Positron emission tomography (PET)-CT showed: (i) systemic multiple lymph node enlargement, abnormal increase of fluorodeoxyglucose metabolism, and spleen infiltration; (ii) nasopharyngeal and oropharyngeal infiltration were not excluded. The patient was clinically diagnosed as IVB stage of AITL.

Immediately after diagnosis, the patient received 7 courses of chemotherapy using recombinant human endostatin (endostar) +CHOP. In each course of chemotherapy, the patient received 15 mg endostar on day 1; injection of 870 mg cyclophosphamide, 4 mg vindesine; and 72 mg pirarubicin on day 2; and 50 mg prednisone tablets twice a day on days 2 to 6. Re-examination by PET-CT showed no systemic swelling or abnormal increase of fluorodeoxyglucose metabolism. Therapeutic efficacy evaluation showed CR, and chemotherapy was then terminated.

About 1 month after the termination of chemotherapy, pharyngalgia reoccurred, and right lymph node was significantly enlarged. Ultrasonography of lymph node showed lymphadenectomy at bilateral neck (maximum on the left, 26 mm × 9 mm; maximum on the right, 35 mm × 11 mm), supraclavicle (maximum, 6 mm × 3 mm), axilla (maximum on the left, 55 mm × 11 mm; maximum on the right, 34 mm × 10 mm), and inguinal (maximum on the left, 26 mm × 8 mm; maximum on the right, 28 mm × 6 mm). Abdominal CT showed multiple lymphadenectomy at abdominal cavity, retroperitoneum, and bilateral inguinal (Fig. 1). Chest CT displayed multiple lymphadenectomy at mediastinum and bilateral axillae (Fig. 2). The patient was considered to have recurrent lymphoma, and then given another 2 courses of chemotherapy. During the chemotherapy, the patient received dexamethasone (20 mg) injection on days 1 to 8, vindesine (4 mg) injection on day 1, VP-16 (70 mg) on days 3–6, cisplatin (30 mg) injection on days 3 to 6, cytosine arabinoside (3 g) on day 8, and endostar (15 mg) on days 1 and 2.

After changing chemotherapy regimen, the therapeutic effect was poor. In addition, the patient was intolerant for the chemotherapy and had severe bone marrow transplantation. Efficacy evaluation result was disease progression. Later, the patient developed systemic rashes at face, trunk, and limbs, with no obvious causes (Fig. 3). In addition, the patient had pruritus, fever (body temperature, 38–39°C), and pharyngalgia, and was considered to have recurrence of lymphoma with skin infiltration.

On March 11, 2016, the patient started to receive chemotherapy with chidamide (30 mg) twice a week + intravenous injections with cyclophosphamide (0.1 g) twice every other day + thalidomide (50 mg) every night. One week later, systemic rashes began to disappear, and nausea, vomiting, and other side effects occurred during oral administration. After 2 courses, the patient began with the oral intake of only chidamide (30 mg) twice a week.
week. Afterward, the patient was followed-up until the writing-up of the report. The condition of the patient was stable, and rashes disappeared, but pigmentation of skin remained (Fig. 3B). In addition, the patient had no pharyngalgia, chills, fever, cough, or expectoration, and the sizes of lymph nodes were significantly reduced. Re-examination by ultrasonography of lymph nodes showed multiple elliptical low echoes at right supraclavicle (maximum of 8 mm x 5 mm), bilateral oxters (maximum of 16 mm x 3 mm), and bilateral inguens (maximum of 6 mm x 3 mm). On August 31st, chest CT showed multiple small lymph nodes at mediastinum and axillas (Fig. 4). Abdominal CT showed no lymphadenectasis (Fig. 5).

3. Discussion

AITL is a highly heterogeneous malignant disease that has rapid clinical progress and strong invasiveness. The occurrence of AITL may be related with infections, inherent causes, or immunodeficiency. About 70%–100% of the AITL patients have EBV infection.\(^7,8\) The mechanism of EBV may be related with abnormal immune functions caused by EBV infection. In the hosts, EBV infects immunocytes such as B cells, T cells, and natural killer cells, and impairs immune functions that can clear neoplastic cells in the body. As a result, neoplastic cells proliferate, leading to the occurrence of tumors. Systemic symptoms of AITL include systemic lymphadenectasis, fever, and rashes.\(^2,4–6,9\) The case reported herein had shown rashes, lymphadenectasis, hepatosplenomegaly, and EBV infection. The chemotherapy regimens for AITL were CHOP, CVP, or VAP, but their complete remission rates are lower than 50%.\(^10\) It is reported that chemotherapy of AITL with endostar combined with CHOPT results in 7 cases of complete remission (50%) and 4 cases of progressive disease (28.6%).\(^11\) The symptoms of the AITL patient in the present case report had been quickly alleviated after administering endostar+CHOP regimen, but the duration of remission was very short, with recurrence and progression, in line with previous reports.\(^12,13\) Early hematopoietic stem cell transplantation can prolong the patients’ survival time.\(^14\) A multicenter retrospective study shows that high-dose chemotherapy combined with autologous stem cell transplantation on 146 AITL patients result in 1- and 2-year survival rates of 67% and 59%, respectively, and 1- and 2-year disease-free survival rates of 70% and 56%, respectively, for CR patients.\(^15\)

The patient in the present report had AITL for 1 year. After 7 courses of chemotherapy with endostar and CHOP, the patient had CR, but later reported recurrence. After changing chemotherapy regimens, the therapeutic efficacy was not satisfactory, and the patient had developed systemic skin infiltration. Then, the patient was classified to have relapsed refractory PTCL with poor prognosis.\(^12,13\) After trying a variety of chemotherapy regimens, chidamide achieved significant efficacy in the treatment of AITL.

Chidamide is the first original patent drug in China that is authorized to be sold in developed countries,\(^16\) and it has good effects for the treatment of relapsed refractory AITL.\(^17,18\) Chidamide inhibits activities of HDAC1, 2, 3, 10 in lymphoma cells,\(^19,20\) interferes with the binding between histone and DNA, suppresses T lymphoma cell growth, and promotes the apoptosis of T lymphoma cells.\(^21,22\)

A phase II clinical trial by Shi et al.\(^23\) shows that chidamide has therapeutic effect on peripheral T lymphoma. Another clinical trial on 83 refractory PTCL patients who are orally given 30mg chidamide twice a week shows that 79 cases can be used for statistical analysis. Among the 79 cases, 28% (22/79) cases have objective response rate (ORR), including 14% cases of CR (11/79). The progression-free survival (PFS) and overall survival (OS) are 2.1 and 21.4 months, respectively. Notably, the effective rate for AITL cases has achieved 50% (5/10), CR accounts for 40% (4/10), and median OS is 21.4 months. Based on this trial, chidamide has been approved by China Food and Drug Administration for the treatment of relapsed refractory PTCL.\(^16\)

In conclusion, the present case report showed that the AITL patient had received unsatisfactory therapeutic efficacy even after 9 courses of chemotherapy. After additional chemotherapy with chidamide combined with cyclophosphamide, the symptoms were alleviated. By the time of manuscript preparation, it has been 9 months since the patient begins to receive oral intake of chidamide. Rashes have subsided, and the sizes of lymph nodes have been significantly reduced, suggesting that chidamide has satisfactory therapeutic efficacy in the treatment of AITL, which provides a novel therapeutic strategy for relapsed refractory AITL. However, more cases are still needed to further validate its efficacy.
References

[1] Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–30.
[2] Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2008;111:4463–70.
[3] Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 2002;13:140–9.
[4] Dogan A, Artyagle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Brit J Haematol 2003;121:681–91.
[5] Federico M, Rudiger T, Belles M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013;31:240–6.
[6] Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a single center cooperative study in Japan. Blood 2012;119:2817–43.
[7] Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein–Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79:1789–95.
[8] Au WY, Ma SY, Chum CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206–14.
[9] Quintanilla-Martinez L, Lome-Maldonado C, Ott G, et al. Primary non-Hodgkin’s lymphoma of the intestine: high prevalence of Epstein–Barr virus in Mexican lymphomas as compared with European cases. Blood 1997;89:644–51.
[10] Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligosclerental T-cell receptor V beta gene expansion. Blood 1997;89:32–40.
[11] Chen QQ, Wang HQ, Zhang HL, et al. Endostar in combination with CHOPT regimen for AITL. J Pract Oncol 2013;30:60–4.
[12] Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leak Lymphoma 1999;32:545–52.
[13] Siegert W, Nerb C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995;6:659–64.
[14] Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970–6.
[15] Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphomas: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218–24.
[16] Administration CfaD. Approval summary for Epidaza® (Chidamide). Available at: www.cde.org.cn/reviewDe.do?method=showFAQ&id= 127. Accessed on February 9, 2015.
[17] Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631–6.
[18] Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109–15.
[19] Gu R, Liu T, Zhu X, et al. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 2015;1000:181–6.
[20] Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 2012;69:901–9.
[21] Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51.
[22] Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, and 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009;54:688–98.
[23] Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 2015;26:1766–71.